Cargando…
1554. Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis
BACKGROUND: Pulmonary mucormycosis, a life-threatening infection of immunocompromised individuals, can have a 95% mortality rate, even with treatment. Intravenous (IV) liposomal amphotericin B (AmBisomeâ, AmBi) is used to treat the infection, but rapid growth of the pathogen can limit the drug’s eff...
Autores principales: | Sandoval, Adilene, Adler-Moore, Jill |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810164/ http://dx.doi.org/10.1093/ofid/ofz360.1418 |
Ejemplares similares
-
1577. Particle Characterization of Nebulized Liposomal Amphotericin B and Its Use in the Treatment of Murine Pulmonary Aspergillosis
por: Dave, Janam J, et al.
Publicado: (2019) -
1639. Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Strains
por: Olson, Jon, et al.
Publicado: (2018) -
Successful treatment of cutaneous mucormycosis disseminated from pulmonary mucormycosis with liposomal amphotericin B and posaconazole
por: Ding, Xiao-Lan, et al.
Publicado: (2020) -
745. Combination Treatment of Liposomal Amphotericin B and Isavuconazole is Synergistic in Treating Experimental Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020) -
845. Clinical Outcomes in Patients Treated with High vs. Standard Dose Liposomal Amphotericin B for Invasive Mucormycosis
por: Valiante, Sarah, et al.
Publicado: (2023)